Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.